{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:48:49Z","timestamp":1785728929582,"version":"3.56.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>COVID-19 convalescent plasma (CCP) obtained from recently recovered people is safe and effective against SARS-CoV-2. Currently available CCP is a \u201chybrid\u201d product with antibodies from individuals who had both infection and vaccination (vaccine-boosted CCP). B-cell depleted patients are at risk of not producing antibodies after either infection or vaccination, hence conceivably among those who would benefit the most from CCP. We thus conducted a systematic review and individual participant data meta-analysis to assess characteristics associated with 60-day survival in B-cell depleted patients transfused with CCP. The protocol was registered with PROSPERO (CRD42024516513) on March 1st, 2024. The last search was on April 2nd, 2024, and included all studies using CCP in B-cell depleted patients. Whenever not available, we requested individual participant data from corresponding authors of eligible studies. Risk of bias was assessed using Joanna Briggs Institute Critical Appraisal Tools. Data were analyzed using conditional logistic regression. The overall 60-day survival rate was 86.5% in our cohort of 570 patients (85 included studies). After controlling for age, sex, calendar year of infection and World Health Organization (WHO) disease severity, we found a significant association between 60-day survival and transfusion of vaccine-boosted CCP (OR\u202f=\u202f9.49; 95% CI 2.01\u201344.82; <jats:italic>p<\/jats:italic>\u202f=\u202f0.005). Overall survival in our cohort of B-cell depleted patients was consistent with prior meta-analysis of randomized controlled trials on survival of immunocompromised patient transfused with CCP (~84%). A novel finding from this analysis is that vaccine-boosted CCP is associated with a high survival benefit.<\/jats:p>","DOI":"10.3389\/fmed.2025.1658593","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:31:34Z","timestamp":1760679094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Solomiia","family":"Zaremba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyatt W.","family":"Pruter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana B.","family":"Collantes Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidna M.","family":"Tulledge-Scheitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hueso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin E.","family":"Juskewitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille M.","family":"van Buskirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund R.","family":"Razonable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Denkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Simeunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahema","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Chaussade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickey E.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon W.","family":"Senefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Joyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/JCO.22.02403","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"41","author":"McLaughlin","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for Cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; king\u2019s college hospital experience","volume":"190","author":"Shah","year":"2020","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.16896","article-title":"Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature","volume":"190","author":"Tepasse","year":"2020","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00277-022-04924-6","article-title":"Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies","volume":"101","author":"Magyari","year":"2022","journal-title":"Ann Hematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e29603","DOI":"10.1002\/jmv.29603","article-title":"Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: a retrospective multicenter study","volume":"96","author":"Destremau","year":"2024","journal-title":"J Med Virol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e00110","DOI":"10.1128\/mbio.00110-24","article-title":"SARS-CoV-2 evolution during prolonged infection in immunocompromised patients","volume":"15","author":"Marques","year":"2024","journal-title":"MBio"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.16525","article-title":"Use of convalescent plasma in COVID-19 patients with immunosuppression","volume":"61","author":"Senefeld","year":"2021","journal-title":"Transfusion"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/cid\/ciad066","article-title":"Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019","volume":"76","author":"Bloch","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e2250647","DOI":"10.1001\/jamanetworkopen.2022.50647","article-title":"COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and Meta-analysis","volume":"6","author":"Senefeld","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/v13081594","article-title":"COVID-19 convalescent plasma is more than neutralizing antibodies: a narrative review of potential beneficial and detrimental co-factors","volume":"13","author":"Focosi","year":"2021","journal-title":"Viruses"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.molmed.2022.02.005","article-title":"Convalescent plasma to deliver therapeutic antibodies against COVID-19","volume":"28","author":"Senefeld","year":"2022","journal-title":"Trends Mol Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s11606-022-07511-7","article-title":"WHO ordinal scale and inflammation risk categories in COVID-19. Comparative study of the severity scales","volume":"37","author":"Rubio-Rivas","year":"2022","journal-title":"J Gen Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","article-title":"Survival analysis part I: basic concepts and first analyses","volume":"89","author":"Clark","year":"2003","journal-title":"Br J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid Synth"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker","year":"2024","journal-title":"JBI Evid Synth"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.11124\/JBIES-22-00224","article-title":"Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews","volume":"21","author":"Munn","year":"2023","journal-title":"JBI Evid Synth"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s43018-022-00503-w","article-title":"Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial","volume":"4","author":"Denkinger","year":"2023","journal-title":"Nat Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e158190","DOI":"10.1172\/JCI158190","article-title":"Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response","volume":"132","author":"Marconato","year":"2022","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/v15030756","article-title":"Convalescent plasma treatment of patients previously treated with B-cell-depleting monoclonal antibodies suffering COVID-19 is associated with reduced re-admission rates","volume":"15","author":"Ioannou","year":"2023","journal-title":"Viruses"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e13272","DOI":"10.1111\/irv.13272","article-title":"Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 omicron SARS-CoV-2","volume":"18","author":"Richier","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","article-title":"Treatment of chronic or relapsing COVID-19 in immunodeficiency","volume":"149","author":"Brown","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/v15010119","article-title":"Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated COVID-19 high-risk patients","volume":"15","author":"Th\u00fcmmler","year":"2023","journal-title":"Viruses"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/hon.3060","article-title":"Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: an Italian retrospective study","volume":"40","author":"Lanza","year":"2022","journal-title":"Hematol Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/hon.2974","article-title":"Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients \u2013 a Czech multicenter experience","volume":"40","author":"Weinbergerov\u00e1","year":"2022","journal-title":"Hematol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e13264","DOI":"10.1111\/irv.13264","article-title":"Real-life comparison of antivirals for SARS-CoV-2 omicron infection in patients with hematologic malignancies","volume":"18","author":"Aiello","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1111\/trf.17083","article-title":"Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients","volume":"62","author":"Weisser","year":"2022","journal-title":"Transfusion"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis","volume":"36","author":"Hueso","year":"2022","journal-title":"Leukemia"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/jmv.27445","article-title":"Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection","volume":"94","author":"Bronstein","year":"2022","journal-title":"J Med Virol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"911339","DOI":"10.3389\/fimmu.2022.911339","article-title":"Clinical Management of Patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway","volume":"13","author":"D\u2019Abramo","year":"2022","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.eimc.2021.01.013","article-title":"Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency \u2013 three consecutive cases and review of the literature","volume":"40","author":"Delgado-Fern\u00e1ndez","year":"2022","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/v14071443","article-title":"Variant of concern-matched COVID-19 convalescent plasma usage in seronegative hospitalized patients","volume":"14","author":"Franchini","year":"2022","journal-title":"Viruses"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000521121","article-title":"Management of persistent SARS-CoV-2 infection in patients with follicular lymphoma","volume":"145","author":"Mart\u00ednez-Barranco","year":"2021","journal-title":"Acta Haematol"},{"key":"ref40","first-page":"62","article-title":"Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-Centre experience and review of the literature","volume":"45","author":"Oliva","year":"2022","journal-title":"New Microbiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7812\/TPP\/21.035","article-title":"Effect of immunosuppressive diseases and rituximab infusions on allowing COVID-19 infection to relapse","volume":"26","author":"Prasad","year":"2022","journal-title":"Perm J"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s15010-022-01821-y","article-title":"Remdesivir in coronavirus disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series","volume":"50","author":"R\u00fcfenacht","year":"2022","journal-title":"Infection"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clml.2021.05.013","article-title":"Dramatic response to convalescent Hyperimmune plasma in association with an extended course of Remdesivir in 4 B cell\u2013depleted non-Hodgkin lymphoma patients with SARS-Cov-2 pneumonia after rituximab therapy","volume":"21","author":"Furlan","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/cid\/ciab647","article-title":"Effects of treatment of coronavirus disease 2019 with convalescent plasma in 25 B-cell\u2013depleted patients","volume":"74","author":"Gharbharan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/diseases12020033","article-title":"A descriptive, retrospective analysis of COVID-19 passive antibody therapy and its effects on morbidity and mortality in patients receiving B-cell-depleting therapies","volume":"12","author":"Gentile","year":"2024","journal-title":"Diseases"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjh.18450","article-title":"Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents","volume":"199","author":"Gachoud","year":"2022","journal-title":"Br J Haematol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/bjh.18540","article-title":"Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy","volume":"200","author":"Gachoud","year":"2023","journal-title":"Br J Haematol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"103278","DOI":"10.1016\/j.transci.2021.103278","article-title":"Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 \u2013 a case series","volume":"60","author":"Erber","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/eji.202149277","article-title":"Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity","volume":"51","author":"Kremer","year":"2021","journal-title":"Eur J Immunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"108723","DOI":"10.1016\/j.clim.2021.108723","article-title":"Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products","volume":"227","author":"Kenig","year":"2021","journal-title":"Clin Immunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell\u2013depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/v15112220","article-title":"Prolonged SARS-CoV-2 infection in patients receiving anti-CD20 monoclonal antibodies: a diagnostic challenged by negative nasopharyngeal RT-PCR and successful treatment with COVID-19 high-titer convalescent plasma","volume":"15","author":"Da Silva","year":"2023","journal-title":"Viruses"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1111\/bjh.18544","article-title":"Lower anti-spike levels in B-cell-depleted patients after convalescent plasma transfusion suggest the need for repeated doses","volume":"200","author":"Focosi","year":"2023","journal-title":"Br J Haematol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1182\/bloodadvances.2022008932","article-title":"Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19","volume":"6","author":"Ripoll","year":"2022","journal-title":"Blood Adv"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/23744235.2021.2013528","article-title":"Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases","volume":"54","author":"Ljungquist","year":"2022","journal-title":"Infect Dis"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e13685","DOI":"10.1111\/tid.13685","article-title":"Convalescent plasma treatment for early post-kidney transplant acquired COVID-19","volume":"23","author":"Kluger","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1186\/s12879-021-06321-2","article-title":"Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience","volume":"21","author":"Cusi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","article-title":"Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies","volume":"62","author":"Ferrari","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1093\/jac\/dkad144","article-title":"High-titer convalescent plasma plus nirmatrelvir\/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients","volume":"78","author":"Huygens","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.22.0577","article-title":"COVID-19 patients treated with convalescent plasma","volume":"143","author":"Nissen-Meyer","year":"2023","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient","volume":"223","author":"Baang","year":"2020","journal-title":"J Infect Dis"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e246308","DOI":"10.1136\/bcr-2021-246308","article-title":"Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use","volume":"14","author":"Adedoyin","year":"2021","journal-title":"BMJ Case Rep"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/infdis\/jiab248","article-title":"Prolonged coronavirus disease 2019 in a patient with rheumatoid arthritis on rituximab therapy","volume":"224","author":"Aviv","year":"2021","journal-title":"J Infect Dis"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.3346\/jkms.2023.38.e175","article-title":"Within-host evolution of SARS-CoV-2 in a B-cell depleted patient with successful treatment","volume":"38","author":"Baek","year":"2023","journal-title":"J Korean Med Sci"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"102983","DOI":"10.1016\/j.transci.2020.102983","article-title":"SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation","volume":"60","author":"Balashov","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.3390\/ijms22168902","article-title":"Clearance of the SARS-CoV-2 virus in an immunocompromised patient mediated by convalescent plasma without B-cell recovery","volume":"22","author":"Basheer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/life12071098","article-title":"Clinical and Virological response to convalescent plasma in a chronic lymphocytic leukemia patient with COVID-19 pneumonia","volume":"12","author":"Belcari","year":"2022","journal-title":"Life."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2022.915367","article-title":"Longitudinal analysis of biologic correlates of COVID-19 resolution: case report","author":"Bruiners","year":"2022","journal-title":"Front Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.clinpr.2021.100096","article-title":"Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: a case report","volume":"12","author":"Casarola","year":"2021","journal-title":"Clin Infect Pract"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3760\/cma.j.cn112147-20230829-00112","article-title":"A case of follicular lymphoma with recurrent fever and pulmonary infiltrates","volume":"47","author":"Chen","year":"2024","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/bjh.16981","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br J Haematol"},{"key":"ref72","first-page":"77","volume-title":"COVID-19-associated pneumonia in a B-cell-depleted patient with non-Hodgkin lymphoma: recovery with","author":"Colombo","year":"2022"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"826883","DOI":"10.3389\/fmicb.2022.826883","article-title":"Emergence of progressive mutations in SARS-CoV-2 from a hematologic patient with prolonged viral replication","volume":"13","author":"Garcia-Vidal","year":"2022","journal-title":"Front Microbiol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"ofab176","DOI":"10.1093\/ofid\/ofab176","article-title":"Prolonged SARS-CoV-2 illness in a patient receiving Ocrelizumab for multiple sclerosis","volume":"8","author":"Gibson","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","article-title":"Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of Remdesivir therapy","volume":"222","author":"Helleberg","year":"2020","journal-title":"J Infect Dis"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.xcrm.2020.100164","article-title":"Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency","volume":"2","author":"Honjo","year":"2021","journal-title":"Cell Reports Medicine"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1017\/ice.2021.120","article-title":"Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient","volume":"43","author":"Hughes","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.3390\/ijms222010934","article-title":"Successful treatment of persistent SARS-CoV-2 infection in a B-cell depleted patient with activated cytotoxic T and NK cells: a case report","volume":"22","author":"Jassem","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e0858","DOI":"10.1002\/rcr2.858","article-title":"Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report","volume":"9","author":"Karaolidou","year":"2021","journal-title":"Respirology Case Reports"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1038\/s41467-022-32772-5","article-title":"Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection","volume":"13","author":"Khatamzas","year":"2022","journal-title":"Nat Commun"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-020-00968-1","article-title":"Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia","volume":"13","author":"Lancman","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"e54564","DOI":"10.7759\/cureus.54564","article-title":"SARS-CoV-2 persistence in immunocompromised patients requiring treatment with convalescent plasma: a case report","volume":"16","author":"Librizzi","year":"2024","journal-title":"Cureus"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"e4020","DOI":"10.1093\/cid\/ciaa1637","article-title":"Sustained response after Remdesivir and convalescent plasma therapy in a B-cell\u2013depleted patient with protracted coronavirus disease 2019 (COVID-19)","volume":"73","author":"Malsy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"860891","DOI":"10.3389\/fimmu.2022.860891","article-title":"Persistence of SARS-CoV-2 infection in severely immunocompromised patients with complete remission B-cell lymphoma and anti-CD20 monoclonal antibody therapy: a case report of two cases","volume":"13","author":"Mart\u00ednez-Chinchilla","year":"2022","journal-title":"Front Immunol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1093\/cid\/ciaa1474","article-title":"Emerging RNA-dependent RNA polymerase mutation in a Remdesivir-treated B-cell Immunodeficient patient with protracted coronavirus disease 2019","volume":"73","author":"Martinot","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s10875-021-00996-7","article-title":"Resolution of persistent COVID-19 after convalescent plasma in a patient with B cell aplasia","volume":"41","author":"McKemey","year":"2021","journal-title":"J Clin Immunol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"e927812","DOI":"10.12659\/AJCR.927812","article-title":"A 63-year-old woman with a history of non-Hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma","volume":"21","author":"Moore","year":"2020","journal-title":"Am J Case Rep"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"e244853","DOI":"10.1136\/bcr-2021-244853","article-title":"High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection","volume":"14","author":"Moutinho-Pereira","year":"2021","journal-title":"BMJ Case Rep"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41409-020-0972-8","article-title":"COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma","volume":"55","author":"Niu","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.mayocp.2021.11.001","article-title":"Vax-plasma in patients with refractory COVID-19","volume":"97","author":"Ordaya","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"103104","DOI":"10.1016\/j.transci.2021.103104","article-title":"Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma","volume":"60","author":"Ormazabal V\u00e9lez","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41375-021-01175-8","article-title":"Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection","volume":"35","author":"Reuken","year":"2021","journal-title":"Leukemia"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.tracli.2021.04.004","article-title":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","volume":"28","author":"Rnjak","year":"2021","journal-title":"Transfus Clin Biol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00296-021-04905-4","article-title":"COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review","volume":"41","author":"Rodriguez-Pla","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1111\/bjh.17806","article-title":"Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response","volume":"196","author":"Schenker","year":"2022","journal-title":"Br J Haematol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"e255255","DOI":"10.1136\/bcr-2023-255255","article-title":"SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing","volume":"16","author":"Seth-Smith","year":"2023","journal-title":"BMJ Case Rep"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10875-022-01313-6","article-title":"Long-term SARS-CoV-2 asymptomatic carriage in an immunocompromised host: clinical, immunological, and Virological implications","volume":"42","author":"Spinicci","year":"2022","journal-title":"J Clin Immunol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12015-020-10107-5","article-title":"Usefulness of plasma SARS-CoV-2 RNA quantification by droplet-based digital PCR to monitor treatment against COVID-19 in a B-cell lymphoma patient","volume":"17","author":"Szwebel","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12941-021-00491-2","article-title":"Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy","volume":"20","author":"Taha","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/life13061266","article-title":"Efficacy of convalescent plasma to treat long-standing COVID-19 in patients with B-cell depletion","volume":"13","author":"Tomisti","year":"2023","journal-title":"Life"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/v15020377","article-title":"SARS-CoV-2 genome variations in viral shedding of an immunocompromised patient with non-Hodgkin\u2019s lymphoma","volume":"15","author":"Villase\u00f1or-Echavarri","year":"2023","journal-title":"Viruses"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clml.2020.06.012","article-title":"Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma","volume":"21","author":"Wright","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.2147\/IDR.S439795","article-title":"Migratory pulmonary infiltrates in a B-cell-depleted COVID-19 patient","volume":"16","author":"Zhu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"613502","DOI":"10.3389\/fimmu.2021.613502","article-title":"Case report: stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma therapy with full clinical recovery","volume":"12","author":"Zimmerli","year":"2021","journal-title":"Front Immunol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","article-title":"High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape","volume":"600","author":"Schmidt","year":"2021","journal-title":"Nature"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from Covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"107323","DOI":"10.1016\/j.ijid.2024.107323","article-title":"Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis optica spectrum disorder with Covid-19: a multicenter retrospective study","volume":"151","author":"Dequidt","year":"2025","journal-title":"Int J Infect Dis"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.7189\/jogh.11.10001","article-title":"Risk factors for poor outcomes in hospitalised COVID-19 patients: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"J Glob Health"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1093\/cid\/ciab954","article-title":"Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study","volume":"75","author":"Madelon","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"103636","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/cid\/ciad460","article-title":"Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice","volume":"77","author":"Mozaffari","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12879-024-09482-y","article-title":"Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study","volume":"24","author":"Zong","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"e0115422","DOI":"10.1128\/spectrum.01154-22","article-title":"Limited correlation between SARS-CoV-2 serologic assays for identification of high-titer COVID-19 convalescent plasma using FDA thresholds","volume":"10","author":"Larkey","year":"2022","journal-title":"Microbiol Spectr"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17476348.2023.2208349","article-title":"Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy","volume":"17","author":"Casadevall","year":"2023","journal-title":"Expert Rev Respir Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1658593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:31:36Z","timestamp":1760679096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1658593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":115,"alternative-id":["10.3389\/fmed.2025.1658593"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1658593","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1658593"}}